Helen Torley - Nov 8, 2021 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
President and CEO, Director
Signature
/s/ James R. Oehler as attorney-in-fact for Helen Torley
Stock symbol
HALO
Transactions as of
Nov 8, 2021
Transactions value $
-$1,990,768
Form type
4
Date filed
11/8/2021, 05:22 PM
Previous filing
Oct 4, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $733K +50K +9.31% $14.66 587K Nov 8, 2021 Direct F1
transaction HALO Common Stock Sale -$1.5M -37.8K -6.43% $39.62 549K Nov 8, 2021 Direct F1, F2
transaction HALO Common Stock Sale -$494K -12.2K -2.23% $40.42 537K Nov 8, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -$733K -50K -25% $14.66 150K Nov 8, 2021 Common Stock 50K $14.66 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1.
F2 Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.25 to $40.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.